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A B S T R A C T
Forkhead box (FOX) F2 and FOXC2 belong to the FOX transcription factor superfamily. FOXC2 is recog-
nized as an inducer of epithelial–mesenchymal transition (EMT), and its overexpression promotes basal-
like breast cancer (BLBC) metastasis. Our previous study demonstrated that FOXF2 functions as an EMT
suppressor and that FOXF2 deﬁciency promotes BLBC metastasis. However, the relationship between the
opposite EMT-related transcription factors FOXF2 and FOXC2 remains unknown. Here, we found that FOXF2
directly targets FOXC2 to negatively regulate FOXC2 transcription in BLBC cells. Functionally, we ob-
served that FOXC2 mediates the FOXF2-regulated EMT phenotype, aggressive behavior, and multiple
chemotherapy drug resistance of BLBC cells. Additionally, we detected a signiﬁcant negative correlation
between the FOXF2 and FOXC2 mRNA levels in triple-negative breast cancer (TNBC) tissues. TNBC pa-
tients in the FOXF2high/FOXC2low and FOXF2low/FOXC2high groups exhibited the best and worst disease-free
survival (DFS), respectively, whereas the patients in the FOXF2high/FOXC2high and FOXF2low/FOXC2low groups
exhibited moderate DFS. In summary, we found that FOXF2 transcriptionally targets FOXC2 and sup-
presses EMT and multidrug resistance by negatively regulating the transcription of FOXC2 in BLBC cells.
The combined expression levels of FOXF2 and FOXC2 mRNA might serve as an effective prognostic indi-
cator and could guide tailored therapy for TNBC or BLBC patients.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Breast cancer is the most frequently diagnosed cancer and is the
leading cause of cancer death among women [1]. Breast cancer is
a heterogeneous disease that can be classiﬁed based on gene ex-
pression proﬁling into biologically distinct intrinsic subtypes
including luminal subtypes A and B, HER2-positive, basal-like, and
normal-like breast cancer. These subtype tumors exhibit uniquemo-
lecular characteristics and prognostic signiﬁcance [2]. The luminal
tumor subtypes maintain a more differentiated state and confer a
more favorable patient prognosis than other tumor subtypes. Al-
though basal-like breast cancer (BLBC) only accounts for 10–20%
of all breast cancers, this subtype has drawn particular attention
due to its poor differentiation status, aggressive phenotype and un-
favorable clinical outcome [3]. BLBC lacks the expression of estrogen
receptor (ER), progesterone receptor (PR) and epidermal growth
factor receptor 2 (HER2). Thus, the deﬁnition of BLBC overlaps with
that of triple-negative breast cancer (TNBC), and TNBC/BLBC pa-
tients would not be expected to beneﬁt from anti-hormonal-
based or anti-HER2 molecularly targeted therapies [4]. A better
understanding of the molecular regulatory mechanisms underly-
ing the different breast cancer subtypes would contribute to the
development of molecularmarkers for the evaluation of patient prog-
nosis and the prediction of drug resistance, which in turn could
provide effective therapeutic strategies for the breast cancer pa-
tients with aggressive biological subtypes.
Epithelial–mesenchymal transition (EMT) is an important mech-
anism that induces epithelial cells to lose their polarity and become
migratory mesenchymal cells, and enables cancer cells to acquire
the ability to complete various steps in the metastatic cascade [5].
In EMT programming, pleiotropic EMT-related transcription factors
(EMT-TFs), such as TWIST1, SNAIL1, SNAIL2, ZEB1 and ZEB2, form
an interaction network in concert to regulate the EMT phenotype
[6]. The EMT process allows the reversion of differentiated cells to
a primitive, mesenchymal stem cell-like phenotype [7,8], which is
an inherent characteristic of normal basal stem cells [9]. It is known
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that the myoepithelial cells derived from differentiation of normal
basal stem cells can attain a mesenchymal-like phenotype by ac-
tivatingmesenchymal EMT-TFs. Conversely, mesenchymal cells could
acquire differentiated epithelial traits via a mesenchymal-to-
epithelial transition (MET) [9]. However, the role and mechanism
underlying myoepithelial cell transformation to a mesenchymal-
like phenotype remain to be determined.
The Forkhead-box (FOX) transcription factor superfamily is char-
acterized by a highly conserved Forkhead/winged helix DNA-
binding domain. These transcription factorsmediate awide spectrum
of biological processes, such as metabolism, differentiation, prolif-
eration, apoptosis, and migration [10,11]. Emerging evidence has
demonstrated that the alterative expression of FOX transcription
factors participate in the onset and progression in a variety of cancers
through directly triggering EMT or cross-linking with other EMT reg-
ulatory pathways [12]. Notably, several FOX transcription factors play
critical roles in cell type-speciﬁc fate decisions, which are associ-
ated with the biological characteristics of breast cancer. FOXA1 is
highly expressed in luminal subtype breast cancer and represses the
molecular phenotypic shift from luminal to basal gene expression
signatures [13]. FOXC2, a mesenchymal FOX transcription factor, is
highly expressed in aggressive BLBC and promotes metastasis and
resistance to paclitaxel drug treatment due to induced mesenchy-
mal differentiation to generate EMT phenotype and cancer stem cell
properties [14,15].
FOXF2, another mesenchymal FOX transcription factor, is spe-
ciﬁcally expressed in the mesenchyme adjacent to the epithelium
in organs derived from the splanchnic mesoderm. FOXF2 plays an
important role in tissue homeostasis by regulating the epithelium–
mesenchyme interaction to maintain epithelial polarity [16]. Our
previous clinical study revealed that the under-expression of
FOXF2 is associated with early-onset metastasis and poor progno-
sis in patients with TNBC [17]. More recent work from our group
revealed that FOXF2 acts as a novel EMT-suppressing transcrip-
tion factor in BLBC cells and that FOXF2 deﬁciency enhances the
metastatic ability of BLBC cells through inducing the EMT program
[18]. In this study, we found that FOXC2 is a novel transcriptional
target of FOXF2 and serves as a mediator of the FOXF2 deﬁciency-
induced EMT phenotype, aggressive behavior and multidrug
resistance of BLBC cells. The combined expression status of FOXF2
and FOXC2 more effectively predicts the prognosis of TNBC pa-
tients than when they were used separately.
Materials and methods
Tissue specimens and clinical data
A total of 156 primary breast cancer tissue specimens diagnosed as invasive ductal
carcinoma were obtained from patients who underwent breast surgery at Tianjin
Medical University Cancer Institute and Hospital (TMUCIH; Tianjin, China). The tumors
were classiﬁed into luminal (ER+ and/or PR+; n = 96), HER2-positive (ER−/PR−/
HER2+; n = 26) and triple-negative (ER−/PR−/HER2−; n = 34) subtypes as described
previously [17]. None of the cases were subjected to preoperative chemotherapy,
and all were followed up for at least 3 years. Of the 156 individuals, 149 cases were
followed up over 5 years. Disease-free survival (DFS) was deﬁned as the time in-
terval between primary surgery and any relapse (local-regional, contra-lateral and/
or distant), or the terminal time of follow-up without any relapse events. This study
was approved by the Institutional Review Board of TMUCIH, and written consent
was obtained from all participants.
Cells and culture
The human immortalized non-tumorigenic mammary epithelial cell line MCF-
10A and breast cancer cell lines MCF-7, T47D, BT474, MDA-MB-453, SKBR-3, MDA-
MB-231, and BT549 were obtained from American Type Culture Collection (Manassas,
VA, USA). The culturing of all cell lines was performed as previously described [18].
Plasmids, small interfering RNA, and transfection
The pcDNA3.1-HA-FOXF2 plasmid expressing HA-tagged FOXF2 (HA-FOXF2)
was obtained as described previously [18]. The FOXC2 promoter region from −1922
to +164 (containing a candidate FOXF2-binding site) or from −1800 to +164
(lacking the candidate FOXF2-binding site) relative to the transcription start site
(TSS) was ampliﬁed from human genomic DNA by PCR. The PCR products were
then inserted into the pGL3-basic luciferase reporter vector (Promega, Madison,
WI, USA; pGL3-FOXC2). Three small interfering RNAs (siRNAs) targeting indepen-
dent sequences of the human FOXF2 (siFOXF2) or FOXC2 (siFOXC2) genes were
synthesized (RiboBio Co., Guangzhou, China). The siRNA displaying optimal knock-
down eﬃciency, as determined by reverse transcription–quantitative PCR (RT-
QPCR) and Western blot, was selected for further experiments. Non-targeting
siRNA was used as a control (siControl). The transfection of cells with plasmids or
siRNAs was performed using Lipofectamine 2000 Reagent (Invitrogen) according
to the manufacturer’s protocol.
Chromatin immunoprecipitation
The HA-FOXF2 plasmid was transfected intoMDA-MB-231 andMCF-7 cells trans-
fected with an HA-FOXF2-expressing plasmid for 48 hours, and a chromatin
immunoprecipitation (ChIP) assay was performed using a ChIP assay kit (Millipore,
Billerica, MA, USA) as previously described [18]. Anti-HA antibody (Abcam, Cam-
bridge, MA, USA)-enriched FOXC2 promoter fragments containing (−1949 to −1774)
and lacking (−1793 to −1592) a putative FOXF2 binding site were PCR ampliﬁed.
Isotype IgG (Abcam) was used as a negative control.
Dual-luciferase reporter assay
Cells were seeded on 24-well plates cultured without antibiotics until growth
to 80% conﬂuence. Then, siFOXF2 or HA-FOXF2 as well as their controls were co-
transfected with FOXC2 promoter constructs and internal control pRL-TK into the
cells. After 48 hours, the luciferase activities of the cells were measured using a dual-
luciferase reporter assay kit (Promega). Reporter luciferase activity was normalized
to Renilla luciferase activity.
RT-QPCR
Total RNA isolation, RT-QPCR, and the quantiﬁcation of target gene expression
were performed as previously described [17]. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA expression was used as an internal control for the
normalization of target gene expression.
Western blot
Cultured cells were collected and solubilized using protein lysis buffer. The pro-
teins were then separated by size using SDS-PAGE and then transferred to polyvinyl
diﬂuoride membrane (Millipore). The membranes were incubated in primary an-
tibodies followed by incubation with the corresponding horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
immunoreactive proteins were detected using an enhanced chemiluminescence kit
(GE Healthcare, Waukesha, WI, USA). The primary antibodies were rabbit anti-HA,
goat anti-FOXC2 (Abcam), mouse anti-E-cadherin, mouse anti-vimentin, mouse anti-
ﬁbronectin (BD Biosciences, Bedford, MA, USA), mouse anti-FOXF2 (Abnova, Taiwan,
China), rabbit anti-integrin β3 (Cell Signaling Technology, Danvers, MA, USA), and
mouse anti-β-actin (Sigma-Aldrich, St. Louis, MO, USA).
Immunoﬂuorescence
Cells were seeded on coverslips and cultured for 48 hours, and then ﬁxed in 4%
paraformaldehyde for 20 min. After washing with PBS, the cells were permeabilized
in 0.5% Triton X-100 for 15min, washed with PBS and blocked with 2% bovine serum
albumin, then incubated with primary antibodies overnight at 4 °C. The cells were
then washed with PBS and incubated with ﬂuorescein isothiocyanate- or
phycoerythrin-conjugated secondary antibodies. Nuclei were stained using DAPI. The
protein labeling was visualized using a ﬂuorescence microscope.
Drug treatment and MTT assay
Cells were seeded on a 96-well plate at a density of 1 × 104 cells/well and cells
subjected to treatment with 0.1 μmol/L paclitaxel, 1.0 μmol/L epirubicin, 25 μmol/L
5-Fu or 1.0 μmol/L cisplatin for 1–3 days. Then, 10 μL of 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT; 5mg/mL in PBS) was added to each well
and incubated for 4 hours. The cell culture medium was replaced with 100 μL of
dimethyl sulfoxide and the optical density was measured at 570 nm. The quantiﬁ-
cation cell viability was determined according to the optical density values for each
culture time point.
Cell migration and invasion assays
The migration and invasion abilities of cells were assessed using non-Matrigel-
coated and Matrigel-coated Transwell inserts (BD Biosciences, San Diego, CA, USA),
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respectively. The assays and counting of migrating or invading cells were per-
formed as described previously [19].
Cell-ﬁbronectin adhesion assay
Cells were seeded on ﬁbronectin-coated 96-well plates at 1 × 105 cells/well and
were incubated in medium for 1.5 hours (MDA-MB-231) or 2 hours (MCF-10A). Then,
the non-adherent cells were removed, and the adherence of cells was estimated by
MTT assay.
Statistical analysis
Data from in vitro experiments are presented as mean ± standard deviation (SD).
Student’s t-test was used to compare the differences between experimental and control
groups. Pearson’s correlation coeﬃcient was calculated to analyze the correlation
between FOXF2 and FOXC2 mRNA expression in breast cancer tissues. Survival plots
were generated by Kaplan–Meier analysis, and the log-rank test was used to assess
the signiﬁcance of the differences. P < 0.05 was considered to be signiﬁcant.
Results
FOXF2 and FOXC2 present distinct expression patterns in different
breast cancer subtypes
To determine the relationship between FOXF2 and FOXC2 ex-
pression, the mRNA levels of FOXF2 and FOXC2 in 156 primary
breast cancer tissues were measured by RT-QPCR. Pearson’s corre-
lation was used to analyze the correlation between FOXF2 and
FOXC2 mRNA levels in all cases and in the cases with different
molecular subtypes. The results for all cases revealed no correlation
between FOXF2 and FOXC2 mRNA levels (Pearson’s r = 0.064,
P = 0.446). Further stratiﬁcation analysis showed that the correla-
tion of FOXF2 and FOXC2 mRNA levels was distinct in different
subtypes: a positive correlation in luminal subtype cases (n = 96;
r = 0.385, P < 0.001), no signiﬁcant correlation in HER2-positive
subtype cases (n = 26; r = 0.29, P = 0.169), and a negative correla-
tion in TNBC cases (n = 34; r = −0.79, P < 0.001; Fig. 1A). The
comparison of FOXF2 or FOXC2 mRNA levels among the groups of
luminal, HER2-positive and triple-negative subtype cases re-
vealed that FOXC2 mRNA levels in the triple-negative group were
signiﬁcant higher than that in the luminal and HER2-positive group;
however, no signiﬁcant differences of FOXF2 mRNA levels among
the three groups were observed (Fig. 1B). FOXF2 and FOXC2 mRNA
levels were also detected in different subtype breast cancer cell
lines. The results showed that both FOXF2 and FOXC2 mRNA levels
are signiﬁcantly high in the triple-negative/basal-like subtype cell
lines, but low in other non-basal-like subtype cell lines (Fig. 1C).
In addition, FOXF2 and FOXC2 mRNA levels presented a reverse
relevant trend in the triple-negative/basal-like subtype cell lines
(Fig. 1C), which is consistent with the result obtained from TNBC
tissues. The negative correlation between FOXF2 and FOXC2 expres-
sion in TNBC is consistent with their opposite roles in the EMT
and metastasis of TNBC/BLBC. The co-expression of FOXF2 and
FOXC2 in luminal tumors implicates that these two transcription
factors play distinct roles in TNBC/BLBC and non-TNBC/BLBC sub-
types. Interestingly, FOXC2 mRNA levels were higher than FOXF2
mRNA levels either in breast cancer tissues or breast cancer cell
Fig. 1. The distinct expression patterns of FOXF2 and FOXC2 in different breast cancer subtypes. The FOXF2 and FOXC2 mRNA levels in primary breast cancer tissues were
measured by RT-QPCR. The assay was performed in triplicate for each sample, and the data quantiﬁcation was normalized to the internal control GAPDH. (A) The correla-
tion between FOXF2 and FOXC2 mRNA levels in overall cases (n = 156), as well as in luminal (n = 96), HER2-positive (n = 26) or triple-negative (n = 34) subtype cases, was
analyzed by Pearson’s correlation analysis. (B) The comparison of FOXF2 or FOXC2 mRNA levels among the groups of luminal, HER2-positive and triple-negative subtype
cases. NS, no signiﬁcant difference among the three groups; P < 0.001, the one-way ANOVA signiﬁcance for triple-negative group compared with luminal and HER2-positive
group. (C) FOXF2 and FOXC2 mRNA levels in different subtype breast cancer cell lines.
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lines, which implies that FOXF2, similar to other multiple EMT
signaling and EMT-TFs [14], is an upstream regulator of FOXC2.
FOXF2 binds to the FOXC2 promoter and uniquely negatively
regulates FOXC2 transcription in BLBC
To investigate whether FOXF2 and FOXC2 transcription factors
transcriptionally regulate each other, we searched the sequences of
the FOXF2 and FOXC2 promoter regions for potential binding sites
of the opposite protein. A conservative FOXF2 binding site (5′-
AATAAACA-3′) was found in the FOXC2 promoter region located
−1845 to −1838 bp from the TSS (Fig. 2A). However, no potential
FOXC2 binding site was found in the FOXF2 promoter region. To de-
termine the binding of FOXF2 to the FOXC2 promoter region, we
performed a ChIP assay in the BLBC cell line MDA-MB-231 and the
luminal breast cancer cell line MCF-7 transfected with an HA-
FOXF2-expressing plasmid using an anti-HA antibody or isotype IgG.
FOXF2-enriched promoter fragments of FOXC2 containing (−1949/
−1774 bp) or lacking (−1793/−1592 bp) the putative FOXF2-binding
elementwere then ampliﬁed by PCR. The results revealed the binding
of FOXF2 to the FOXC2 promoter region containing the FOXF2-
binding element in both the basal-like (MDA-MB-231) and luminal
(MCF-7) breast cancer cells. However, no binding of FOXF2 to the
FOXC2 promoter region in the absence of the FOXF2-binding site was
observed in either cell line (Fig. 2B).
To further determine whether FOXF2 regulates FOXC2 promot-
er activity in both BLBC and luminal subtype breast cancer cells, the
BLBC cell lines MDA-MB-231 (with high FOXF2 expression) and
Fig. 2. FOXF2 binds to the FOXC2 promoter and negatively regulates FOXC2 transcription in BLBC cells. (A) Schematic representation of a conservative FOXF2 binding site
(5′-AATAAACA-3′) in the FOXC2 promoter region located at −1845 to −1838 bp from the TSS. (B) The binding of FOXF2 to the FOXC2 promoter region in MDA-MB-231 and
MCF-7 cells transfected with the HA-FOXF2 expression plasmid was assessed by ChIP assay using an anti-HA antibody. FOXF2-enriched the promoter regions of FOXC2 con-
taining (−1949/−1774) or lacking (−1793/−1592) the putative FOXF2 binding element were ampliﬁed by PCR. Isotype IgG was used as a negative control, and the total input
was used as a positive control. (C) The luciferase activity of the reporters in the indicated cells was assessed by a dual-luciferase reporter assay. The experiment was re-
peated twice in duplicate. The relative luciferase activity is the ratio of the luciferase activity in each test cells to that in the control cells. The data are expressed as mean ± SD.
*P < 0.05 compared with the control cells. (D) The mRNA levels of FOXF2 and FOXC2 in the indicated cells were measured by RT-QPCR. The assays were performed indepen-
dently repeated three times in triplicate. The relative mRNA level of each gene is the ratio of the mRNA level in each test cell to that in the control cells, and the data are
expressed as mean ± SD. *P < 0.05 compared to the control cells.
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BT-549 (with low FOXF2 expression) and the luminal cell line MCF-7
(less FOXF2 expression) [18] were subjected to the dual-luciferase
reporter assay. The cells were transiently transfected with siFOXF2
(MDA-MB-231) or FOXF2 plasmid (BT-549 and MCF-7) or the cor-
responding controls. Then, these cells were co-transfected with the
internal control pRL-TK and the FOXC2 promoter-luciferase report-
er construct pGL3-FOXC2 (−1922/+164 bp; containing the FOXF2-
binding element) or pGL3-FOXC2 (−1800/+164 bp; lacking the FOXF2-
binding element). The results demonstrated that the reporter activity
of pGL3-FOXC2 (−1922/+164) was signiﬁcantly increased in the
FOXF2-depleted MDA-MB-231 cells and decreased in the FOXF2-
overexpressed BT-549 cells compared to the corresponding controls.
In contrast, the reporter activity of pGL3-FOXC2 (−1800/+164) was
not signiﬁcantly changed by either FOXF2 depletion or FOXF2
overexpression. Surprisingly, the reporter activity of pGL3-FOXC2
(−1922/+164 bp) was not signiﬁcantly altered in the FOXF2-
overexpressed MCF-7 cells (Fig. 2C). These results indicated that
FOXF2 represses the transcriptional activity of FOXC2 by binding to
the FOXC2 promoter element in BLBC cells, but does not regulate
FOXC2 promoter activity in luminal breast cancer cells.
To verify the regulatory role of FOXF2 on FOXC2 expression in
BLBC and luminal breast cancer cells, the FOXF2 and FOXC2 mRNA
levels were assessed in MDA-MB-231, BT-549 and MCF-7 cells with
RNAi-mediated FOXF2 knockdown or FOXF2 overexpression, as well
as in the corresponding control cells. The results showed that FOXF2
negatively regulated FOXC2 expression in MDA-MB-231 and BT-
549 BLBC cells but did not affect FOXC2 expression in MCF-7 luminal
breast cancer cells (Fig. 2D). Taken together, these results sug-
gested that FOXC2 acts as a direct transcriptional target of FOXF2,
and FOXF2 negatively regulates FOXC2 transcription in BLBC cells.
FOXF2 negatively regulates the FOXC2-mediated EMT phenotype and
programming of BLBC cells
To determine the role of FOXC2 in the FOXF2-regulated EMT of
BLBC cells, we examined the alteration of the EMT phenotype in
basal-like mammary epithelial cell line MCF-10A and BLBC cell line
MDA-MB-231 with the RNAi-mediated FOXF2- or/and FOXC2 knock-
down and the corresponding controls. As expected, FOXF2 depletion
substantially converted MCF-10A and MDA-MB-231 cells to a more
mesenchymal/ﬁbroblast-like morphology with a spindle-like cell
shape and cell scattering (Fig. 3A). The FOXF2-depleted cells dis-
played decreased expression of epithelial marker E-cadherin (CDH1)
and elevated the expression of mesenchymalmarkers vimentin (VIM)
and ﬁbronectin 1 (FN1), as detected by immunoﬂuorescence (Fig. 3A),
RT-QPCR (Fig. 3B) and immunoblotting (Fig. 3C). Conversely, the in-
hibition of FOXC2 resulted in the reduction of this ﬁbroblast-like
morphology, which presents increased epithelial-like cell cluster-
ing, prominent cell–cell contacts, and decreased expression of
mesenchymal markers vimentin and ﬁbronectin (Fig. 3A–C). Im-
portantly, the FOXF2 depletion-induced EMT phenotype was rescued
by FOXC2 knockdown (Fig. 3A–C). In addition, FOXF2 negatively regu-
lated the expression of the FOXC2 target integrin β3 through
suppressing FOXC2 transcription (Fig. 3C). These results indicated
that FOXC2 mediates the FOXF2-regulated EMT phenotype of BLBC
cells.
In EMT programming, pleiotropic EMT-TFs form an interaction
network and act in concert to regulate the EMT phenotype. To further
investigate whether FOXC2 mediates FOXF2-regulated EMT pro-
gramming in the EMT-TF interaction network, we examined the
mRNA expression of EMT-TFs TWIST1, SNAIL1, SNAIL2, ZEB1 and ZEB2
in the above cells. The results revealed that FOXF2 depletion sig-
niﬁcantly upregulated TWIST1, SNAIL2, ZEB1, and ZEB2 expression
in MCF-10A and MDA-MB-231 cells, while FOXC2 knockdown
downregulated the mRNA expression of these EMT-TFs. Consis-
tent with the EMT phenotype of the MCF-10A and MDA-MB-231
cells with FOXF2 and FOXC2 knockdown, FOXF2 depletion-induced
EMT-TF expression was reversed by FOXC2 knockdown (Fig. 3D).
These results indicated that FOXC2 mediates the FOXF2-regulated
EMT programming in BLBC cells.
FOXC2 mediates the FOXF2-regulated aggressive behavior of BLBC
cells
Since FOXF2 negatively regulates FOXC2-mediated EMT and ex-
pression of adhesion molecule integrin β3 in BLBC cells, we further
investigated whether FOXC2 mediates the FOXF2-regulated aggres-
sive phenotype of BLBC cells. The migration, invasion and adhesion
abilities of the MCF-10A-siFOXF2 and MDA-MB-231-siFOXF2 cells
were assessed by Transwell and cell–ﬁbronectin (a ligand of integrin
β3 [20]) adhesion assays. The transwell assays showed that FOXF2
depletion induced a dramatic increase of the migration and inva-
sion abilities of MCF-10A and MDA-MB-231 cells, and this increase
was partially rescued by the inhibition of FOXC2 expression (Fig. 4A
and B). Consistently, the adhesion of cells to ﬁbronectin was induced
by FOXF2 knockdown, and this interaction was abolished by FOXC2
depletion (Fig. 4C). These results indicated that FOXC2 mediates the
FOXF2-regulated aggressive behavior of BLBC cells.
FOXF2 depletion enhances the multidrug resistance of BLBC cells
through targeting FOXC2
Since the EMT generates cells exhibiting the properties of stem
cells [8] and the acquisition of stem cell properties increases their
resistance to chemotherapeutic agents [21], we further tested
whether FOXF2 and FOXC2 contribute to the drug resistance of breast
cancer cells. The chemotherapy drugs commonly used for the clin-
ical treatment of breast cancer, including paclitaxel, epirubicin,
5-ﬂuorouracil (5-Fu) and cisplatin, were used to treat MDA-MB-
231 cells transfected with siFOXF2 or/and siFOXC2. MTT assays
revealed that FOXF2 depletion led these cells to become more re-
sistant to these drugs, while FOXC2 knockdown resulted in
signiﬁcantly increased sensitization compared with the control cells.
Consistently, the chemosensitivity of cells co-transfected with
siFOXF2 and siFOXC2 was between that of the cells transfected with
siFOXF2 or siFOXC2 alone (Fig. 5). These results suggested that FOXF2
and FOXC2 play opposite roles in the multidrug resistance of BLBC
cells.
The combination of FOXF2 and FOXC2 mRNA levels effectively
predicts the prognosis of TNBC patients
Based on our novel ﬁndings that FOXF2 and FOXC2 are in-
versely expressed in TNBC tissues and that these transcription factors
play opposite roles in regulating the EMT phenotype and aggres-
sive behavior of BLBC cells, we next addressedwhether the combined
detection of FOXF2 and FOXC2mRNA levels effectively predicts TNBC
patient prognosis. Thus, we grouped the 34 cases of TNBC and 122
cases of non-TNBC based on their FOXF2 and FOXC2 mRNA levels:
FOXF2high/FOXC2low, FOXF2high/FOXC2high, FOXF2low/FOXC2low, and
FOXF2low/FOXC2high. Kaplan–Meier analysis revealed that in TNBC
cases, patients in the FOXF2high/FOXC2low and FOXF2low/FOXC2high groups
exhibited the best and worst DFS, respectively, while patients in the
FOXF2high/FOXC2high and FOXF2low/FOXC2low groups exhibited moder-
ate DFS (Fig. 6A). In contrast, FOXF2 and FOXC2 mRNA levels did not
distinguish DFS in the non-TNBC cases (Fig. 6B). These results sug-
gested that FOXC2low may contribute to the FOXF2high-suppressed
recurrence and metastasis of TNBC and that FOXC2high may facili-
tate the FOXF2low-resulted unfavorable prognosis in TNBC. FOXC2
functionally mediates the effect of FOXF2 on BLBC/TNBCmetastasis,
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Fig. 3. FOXF2 negatively regulates the FOXC2-mediated EMT phenotype and programming of BLBC cells. (A) Themorphology of MCF-10A andMDA-MB-231 cells transfected
with siFOXF2 or/and siFOXC2 as well as their controls. (B) The protein expression levels of mesenchymal markers vimentin (red) and ﬁbronectin 1 (green) in the indicated
cells were detected by immunoﬂuorescence. DAPI (blue) was used to reveal the nucleus. (C) The mRNA expression levels of VIM and FN1 in the indicated cells were measured
by RT-QPCR. (D) The protein expression levels of E-cadherin, vimentin, ﬁbronectin 1 and integrin β3 in the indicated cells were detected by immunoblotting. β-actin was used
as the internal control. (E) The mRNA expression levels of the EMT-TFs TWIST1, SNAIL1, SNAIL2, ZEB1 and ZEB2 in the indicated cells were measured by RT-QPCR. *P < 0.05,
transfection with siFOXC2 or siFOXF2 versus the control treatment; #P < 0.05, co-transfection with siFOXC2 and siFOXF2 versus transfection with siFOXF2 alone.
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and the combined detection of FOXF2 and FOXC2 mRNA levels ef-
fectively predicts the prognosis of TNBC patients.
Discussion
During acquirement of the EMT phenotypes to complete the
cascade of metastatic spread, embryonic and mesenchymal tran-
scription factors are pleiotropically activated in cancer cells.
Mesenchymal FOXC2 has been reported to be induced in response
to multiple signaling (e.g. TGFβ1) and EMT-TFs (e.g. SNAIL, TWIST,
and Goosecoid) and acts as a central mediator that orchestrates the
mesenchymal component of the EMT program and promotes me-
tastasis in BLBC. FOXC2 expression is correlated with highly
aggressive BLBC and considered to be a highly speciﬁc molecular
marker for BLBC [14]. Our previous study demonstrated that FOXF2
is highly expressed in most basal-like breast cells and functions as
an EMT-suppressing transcription factor. FOXF2 deﬁciency pro-
motes metastasis of BLBC cells by activating the EMT program. We
also demonstrated that FOXF2 negatively targets TWIST1 in the EMT
programming and metastasis progress of BLBC [18]. On the basis
of our ﬁnding, we proposed that FOXF2, as a mesenchymal FOX tran-
scription factor, acts cooperatively with TWIST1 to maintain tissue
homeostasis by balancing the differentiation or dedifferentiation of
mesenchymal/myoepithelial cells. In the current study, we dem-
onstrated that FOXC2, which was similar with TWIST1, functions
as a transcriptional target of FOXF2 in BLBC cells but not in luminal
breast cancer cells. FOXC2 is a novel mediator of FOXF2 deﬁciency-
induced mesenchymal differentiation during the EMT. This ﬁnding
provided a novel regulatory pathway of the FOXC2-mediated EMT-
TF interaction network during the EMT programming andmetastatic
cascade of BLBC cells. The FOXF2/FOXC2-regulated EMT may serve
as a therapeutic target for the treatment of aggressive BLBC.
Integrins are heterodimeric transmembrane receptors for com-
ponents of the extracellular matrix (ECM), such as ﬁbronectin,
laminin, collagen, ﬁbrinogen, and vitronectin. Through bidirec-
tional “outside-in” and “inside-out” signaling, integrins regulate
multiple biological processes, such as adhesion, apoptosis, prolif-
eration, differentiation, migration, invasion, andmetastasis [22]. The
integrin β3 subunit and its integrin heterodimers are associated with
the metastatic processes of breast cancer cells [23]. Fibronectin is
a ubiquitous and abundant ECM protein. αvβ3 integrin could high-
aﬃnity bind ﬁbronectin by interaction with the N-terminal of the
FN-I type module [20]. Fibronectin–integrin interactions play an im-
portant role in cell adhesion, migration and invasion by activating
integrin-linked signaling [24]. Hayashi et al. [25] reported that FOXC2
induces the expression of the integrin β3 subunit by directly binding
to the ITGB3 promoter, thereby regulating integrin β3-mediated en-
dothelial cell adhesion and migration. In our study, we found that
FOXC2 mediates FOXF2-regulated integrin β3 expression and cell-
ﬁbronectin adhesion in BLBC cells, suggesting that integrin β3 is
regulated by the FOXF2/FOXC2 pathway and contributes to the ac-
quisition of the aggressive properties of BLBC cells.
TNBC/BLBC is a subtype of breast cancer associated with poor
differentiation status, aggressive phenotype and unfavorable clin-
ical outcome. TNBC/BLBC could not beneﬁt from anti-hormone
endocrine therapies and anti-HER2 molecularly targeted thera-
pies due to the lack of ER, PR and HER2 expressions [26].
Chemotherapy is the only systemic treatment option for TNBC/
BLBC patients [27]. However, cells undergoing EMT often acquire
resistance to chemotherapeutic agents due to the generation of stem
cell-like properties [21]. Hollier et al. reported that FOXC2 is a crit-
ical determinant of mesenchymal and stem cell-like properties in
cells that undergo EMT and that the suppression of FOXC2 expres-
sion sensitizes these cells to paclitaxel [15]. However, with the
exception of paclitaxel, no evidence is available to demonstrate the
effect of FOXC2 expression on the eﬃcacy of other chemotherapy
drugs routinely used in breast cancer treatment. Furthermore, no
report to date has investigated the role of FOXF2 in the chemosen-
sitivity of breast cancers. In this study, we determined the response
of BLBC cells subjected to FOXF2 or/and FOXC2 inhibition to the fol-
lowing chemotherapy drugs commonly used in the clinical treatment
of breast cancer: paclitaxel, epirubicin, 5-Fu and cisplatin [27]. We
found that FOXF2 and FOXC2 play opposite roles in the treatment
response to all of these chemotherapy drugs. FOXF2 inhibition
Fig. 4. FOXC2mediates the FOXF2-regulated aggressive behavior of BLBC cells. Images
(A) and quantiﬁcation (B) of the migration and invasion abilities of the indicated
cells were assessed by Transwell assays. (C) The adhesion ability of the indicated
cells was assessed by cell–ﬁbronectin adhesion assay. Three independent experi-
ments were performed in triplicate. *P < 0.05, transfection with siFOXF2 or siFOXC2
alone versus the control treatment; #P < 0.05, co-transfectionwith siFOXF2 and siFOXC2
versus transfection with siFOXF2 alone.
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Fig. 5. FOXF2 depletion enhances the multidrug resistance of BLBC cells through targeting FOXC2. The cell viability was assessed by MTT assay. The MDA-MB-231 cells were
transfected with siFOXF2 or/and siFOXC2 as well as their corresponding control cells subjected to treatment with (A) 0.1 μmol/L paclitaxel, (B) 1.0 μmol/L epirubicin, (C)
25 μmol/L 5-Fu or (D) 1.0 μmol/L cisplatin for the indicated times. Three independent experiments were performed in triplicate. *P < 0.05, transfection with siFOXF2 or siFOXC2
alone versus the control treatment; #P < 0.05, co-transfection with siFOXF2 and siFOXC2 versus transfection with siFOXF2 alone.
Fig. 6. The combination of FOXF2 and FOXC2 mRNA levels effectively predicts the prognosis of TNBC patients. Kaplan–Meier survival analysis based on patient’s DFS and
combined FOXF2 and FOXC2 mRNA expression levels in primary TNBC tissues (n = 34; A) or non-TNBC tissues (n = 122; B). The optimal cutoff value of FOXF2 or FOXC2 mRNA
level was determined based on receiver operating characteristic curves at a mutually maximized sensitivity and speciﬁcity to stratify the patients into FOXF2high and FOXF2low
or FOXC2high and FOXC2low groups with distinct DFS status. Log–rank test was used to assess the signiﬁcance of DFS differences among groups with differant FOXF2/FOXC2 status.
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enhanced multidrug resistance, while FOXC2 inhibition reversed
FOXF2 depletion-induced drug resistance. Thus, exogenous admin-
istration of FOXF2 or interference of FOXC2, as well as FOXF2/
FOXC2 pathway, might be eﬃcient strategies for improving the
therapeutic outcomes of chemotherapy for the treatment of TNBC/
BLBC patients.
TNBC/BLBC is heterogeneous with different differentiation char-
acteristics [28]. Therefore, patients with tumors of the TNBC/BLBC
subtype might have distinct prognosis. There is an urgent need
for powerful biological markers to further distinguish the outcome
of breast cancer patients with this tumor subtype. FOXC2 is recog-
nized as a marker of aggressive BLBC [14], and our previous study
found that FOXF2 mRNA levels positively correlate with the prog-
nosis of TNBC patients [17]. In the present study, we further
demonstrated that FOXF2 and FOXC2 mRNA levels are uniquely and
inversely expressed in TNBC, and FOXF2 and FOXC2 play opposite
roles in TNBC/BLBC metastasis. Thus, we assessed the clinical value
of the combined detection of FOXF2 and FOXC2 mRNA levels for
the prognosis of TNBC. We found that TNBC cases could be divided
into distinct DFS subgroups based on the combined FOXF2 and FOXC2
mRNA levels: the patients in the FOXF2high/FOXC2low and FOXF2low/
FOXC2high groups had the best and worst DFS, respectively, while
the patients in the FOXF2high/FOXC2high and FOXF2low/FOXC2low groups
had moderate DFS. The combined detection of FOXF2 and FOXC2
mRNA levels more effectively predicted the prognosis of TNBC pa-
tients than the detection of either factor alone. Although our results
provide a potential powerful gene-based diagnosis for distinguish-
ing the outcome of TNBC subtype patients, the prognostic
signiﬁcance of these two markers for TNBC/BLBC patients re-
quires further validation by expanding the number of clinical cases
from multiple centers.
In conclusion, here, we identiﬁed a novel molecular mecha-
nism of FOXF2 in controlling BLBC metastasis and multidrug
resistance. We found that FOXC2 is a transcriptional target of FOXF2.
FOXF2 suppresses the EMT and multidrug resistance through neg-
atively regulating FOXC2 expression in BLBC. The combined FOXF2
and FOXC2 mRNA levels in primary breast cancers might serve as
an effective prognostic indicator and guide tailored therapy for TNBC
patients. Moreover, targeting the FOXF2/FOXC2 pathway might be
a potential therapeutic strategy for TNBC/BLBC patients.
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